Modality
Bispecific Ab
MOA
KIF18Ai
Target
KRASG12C
Pathway
Innate Imm
HSBladder Ca
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
~Jul 2018
→ ~Oct 2019
Phase 3
Jan 2020
→ Nov 2027
Phase 3Current
NCT07562450
2,525 pts·HS
2020-09→2025-10·Recruiting
NCT04800303
1,231 pts·Bladder Ca
2024-07→2027-11·Active
NCT06393062
197 pts·Bladder Ca
2020-01→2027-02·Not yet recruiting
+1 more trial
5,523 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-10-026mo agoPh3 Readout· HS
2025-10-195mo agoPh3 Readout· Bladder Ca
2027-02-0110mo awayPh3 Readout· Bladder Ca
2027-11-081.6y awayPh3 Readout· Bladder Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Not yet…
P3
Recruit…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2025-10-02 · 6mo ago
HS
Ph3 Readout
2025-10-19 · 5mo ago
Bladder Ca
Ph3 Readout
2027-02-01 · 10mo away
Bladder Ca
Ph3 Readout
2027-11-08 · 1.6y away
Bladder Ca
RecruitingActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07562450 | Phase 3 | HS | Recruiting | 2525 | PFS |
| NCT04800303 | Phase 3 | Bladder Ca | Active | 1231 | Safety |
| NCT06393062 | Phase 3 | Bladder Ca | Not yet recr... | 197 | DAS28 |
| NCT06706215 | Phase 3 | Bladder Ca | Completed | 1570 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |